Skip to main content
NCBI home page
Journal of Clinical Laboratory Analysis logoLink to Journal of Clinical Laboratory Analysis
. 2006 Mar 14;20(2):62–67. doi: 10.1002/jcla.20098

St. John's wort does not interfere with therapeutic drug monitoring of 12 commonly monitored drugs using immunoassays

Amitava Dasgupta 1,✉, Gertie Tso 2, Kathy Szelei‐Stevens 1
PMCID: PMC6807396  PMID: 16538644

Abstract

St. John's wort, a popular herbal remedy for depression, is known to interact with many Western drugs because of the ability of its components to induce liver enzymes. Lower concentrations of various drugs due to increased clearance have been reported. Because immunoassays are commonly used in clinical laboratories for therapeutic drug monitoring, we studied the potential interference of St. John's wort with commonly monitored therapeutic drugs. Drug‐free serum pools were supplemented with St. John's wort to achieve in vitro St. John's wort concentrations mimicking in vivo concentrations after both recommended use and overdose. Concentrations of digoxin, tricyclic antidepressants (TCAs), phenytoin, carbamazepine, theophylline, valproic acid, quinidine, phenobarbital, procainamide, and N‐acetyl procainamide were measured in serum. Pooled serum specimens from patients who were taking a particular drug were also supplemented in vitro with concentrations of St. John's wort to investigate whether observed concentrations changed after supplementation with St. John's wort. The effect of St. John's wort on cyclosporine and tacrolimus (FK 506) was studied in whole blood. We found no significant interference from St. John's wort with any assay studied. Moreover, when drug‐free serum was supplemented with very high concentrations of hypericin (2 µg/mL) and hyperforin (2 µg/mL) pure standard, we observed no apparent drug level with any immunoassay. The presence of both hypericin and hyperforin was also confirmed by thin layer chromatography (TLC) in both preparations of St. John's wort. We conclude that immunoassays may be used to measure levels of therapeutic drugs in patients who self‐medicate with St. John's wort. J. Clin. Lab. Anal. 20:62–67, 2006. © 2006 Wiley‐Liss, Inc.

Keywords: St. John's wort, therapeutic drug monitoring, immunoassay, interference study

REFERENCES

  • 1. Gulla J, Singer AJ, Gaspari R. Herbal use in ED patients. Acad Emerg Med 2001;8:450. [Google Scholar]
  • 2. Mannel M. Drug interactions with St. John's wort: mechanism and clinical implications. Drug Safety 2004;27:773–797. [DOI] [PubMed] [Google Scholar]
  • 3. Fujita K. Food‐drug interactions via human cytochrome P 450 3A (CYP3A4). Drug Metabol Drug Interact 2004;20:195–217. [DOI] [PubMed] [Google Scholar]
  • 4. Mills E, Montori VM, Wu P, Gallicano K, Clarke M, Guyatt G. Interaction of St. John's wort with conventional drugs: systematic clinical trials. BMJ 2004;329:27–30. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Murphy PA, Kern SE, Stanczyk FZ, Westhoff CL. Interaction of St. John's wort with oral contraceptives: effect on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding. Contraception 2005;71:402–408. [DOI] [PubMed] [Google Scholar]
  • 6. Martin‐Facklam M, Rieger K, Riedel KD, Burhenne J, Walter‐Sack I, Haefeli WE. Undeclared exposure of St. John's wort in hospitalized patients. Br J Clin Pharmacol 2004;58:437–441. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Barone GW, Gurley BJ, Ketel BL, Abul‐Ezz SR. Herbal supplements: a potential for drug interactions in transplant recipients. Transplantation 2001;71:239–241. [DOI] [PubMed] [Google Scholar]
  • 8. Bauer S, Stromer E, Johne A, et al. Alteration of cyclosporine A pharmacokinetics and metabolism during treatment with St. John's wort in renal transplant patients. Br J Clin Pharmacol 2003;55:203–211. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Mai I, Bauer S, Perloff ES, Johne A, Uehleke B, et al. Hyperforin content determines the magnitude of the St. John's wort‐cyclosporine drug interaction. Clin Pharmacol 2004;76:330–340. [DOI] [PubMed] [Google Scholar]
  • 10. Hebert MF, Park JM, Chen YL, et al. Effects of St John's wort (Hypercium perforatum) on tacrolimus pharmacokinetics in healthy volunteers. Clin Pharmacol 2004;44:89–94. [DOI] [PubMed] [Google Scholar]
  • 11. Mai I, Stormer E, Bauer S, et al. Impact of St. John's wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. Nephrol Dial Transplant 2003;18:819–822. [DOI] [PubMed] [Google Scholar]
  • 12. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Fallon J. Indinavir concentrations and St. John's wort. Lancet 2000;355:547–548. [DOI] [PubMed] [Google Scholar]
  • 13. Busti AJ, Hall RJ, Margolis DM. Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy 2004;24:1732–1747. [DOI] [PubMed] [Google Scholar]
  • 14. Cvetkovic RS, Goa KL. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs 2003;63:769–802. [DOI] [PubMed] [Google Scholar]
  • 15. Nebel A, Schneider BJ, Kroll DJ. Potential metabolic interaction between St. John's wort and theophylline. Ann Pharmacother 1999;33:502. [DOI] [PubMed] [Google Scholar]
  • 16. Morimoto T, Kotegawa T, Tsutsumi K, Ohtani Y, Imai H, Nakano S. Effect of St. John's wort on the pharmacokinetics of theophylline in healthy volunteers. J Clin Pharmacol 2004;44:95–101. [DOI] [PubMed] [Google Scholar]
  • 17. Eich‐Hochli D, Oppliger R, Golay KP, Baumann P, Eap CB. Methadone maintenance treatment and St. John's wort–a case study. Pharmacopsychiatry 2003;36:35–37. [DOI] [PubMed] [Google Scholar]
  • 18. Smith P. The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate. Pharmacotherapy 2004;24:1508–1514. [DOI] [PubMed] [Google Scholar]
  • 19. Sugimoto K, Ohmori M, Tsuruoka S, et al. Different effect of St. John's wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther 2001;70:518–524. [DOI] [PubMed] [Google Scholar]
  • 20. Burstein AH, Horton RL, Dunn T, Alfaro RM, Piscitelli SC, Theodore W. Lack of effect of St. John's wort on carbamazepine pharmacokinetics in healthy volunteers. Clin Pharmacol Ther 2000;68:605–612. [DOI] [PubMed] [Google Scholar]
  • 21. Johne A, Brockmoller J, Bauer S, et al. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clin Pharmacol Ther 1999;66:338–345. [DOI] [PubMed] [Google Scholar]
  • 22. Durr D, Stieger B, Kullak‐Ublick GA, et al. St John's wort induces intestinal P‐glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 2000;68:598–604. [DOI] [PubMed] [Google Scholar]
  • 23. Muller SC, Uehleke B, Woehling H, et al. Effect of St. John's wort dose and preparation on the pharmacokinetics of digoxin. Clin Pharmacol Ther 2004;75:546–557. [DOI] [PubMed] [Google Scholar]
  • 24. Tannergren C, Engman H, Knutson L, Hedeland M, Bondesson U, Lennernas H. St John's wort decreases the bioavailability of R and S‐verapamil through induction of the first pass metabolism. Clin Pharmacol Ther 2004;75:298–309. [DOI] [PubMed] [Google Scholar]
  • 25. Panesar NS. Bufalin and unidentified substances in traditional Chinese medicine cross react in commercial digoxin assay. Clin Chem 1992;38:2155–2156. [PubMed] [Google Scholar]
  • 26. Dasgupta A, Biddle D, Wells A, Datta P. Positive and negative interference of Chinese medicine Chan Su in serum digoxin measurement: elimination of interference by using a monoclonal chemiluminescent digoxin assay or monitoring free digoxin concentration. Am J Clin Pathol 2000;114:174–179. [DOI] [PubMed] [Google Scholar]
  • 27. Wahed A, Dasgupta A. Positive and negative in vitro interference of Chinese medicine Dan Shen in serum digoxin measurement: elimination of interference by monitoring free digoxin concentration. Am J Clin Pathol 2001;116:403–408. [DOI] [PubMed] [Google Scholar]
  • 28. McRae S. Elevated serum digoxin levels in a patient taking digoxin and Siberian ginseng. CMAJ 1996;155:293–295. [PMC free article] [PubMed] [Google Scholar]
  • 29. Dasgupta A, Wu S, Actor J, Olsen M, Wells A, Datta P. Effect of Asian and Siberian ginseng on serum digoxin measurement by five digoxin immunoassays: significant variation in digoxin‐like immunoreactivity among commercial ginsengs. Am J Clin Pathol 2003;119:298–303. [DOI] [PubMed] [Google Scholar]
  • 30. Chow L, Johnson M, Wells A, Dasgupta A. Effect of traditional Chinese medicines Chan Su, Lu‐Shen‐Wan, DanShen and Asian ginseng on serum digoxin measurement by Tina‐Quant (Roche) and Synchron LX system (Beckman) digoxin immunoassays. J Clin Lab Anal 2003;17:22–27. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31. Orth HC, Rentel C, Schmidt PC. Isolation, purity analysis and stability of hyperforin as a standard material from Hypericum perforatum L . J Pharm Pharmacol 1999;51:193–200. [DOI] [PubMed] [Google Scholar]
  • 32. Miller JJ, Valdes R. Methods for calculating cross reactivity in immunoassays. J Clin Immunoassay 1992;15:97–100. [Google Scholar]
  • 33. Schempp CM, Winghofer B, Langheinrich M, Schopf E, Simon JC. Hypericin levels in human serum and interstitial skin blister fluid after oral single dose and steady state administration of Hypericum perforatum extract (St. John's wort). Skin Pharmacol Appl Skin Physiol 1999;12:299–304. [DOI] [PubMed] [Google Scholar]
  • 34. Staffeldt B, Kerb R, Brockmoller J, Ploch M, Roots I. Pharmacokinetics of hypericin and pseudohypericin after oral intake of Hypericium perforatum extract LI 160 in healthy volunteers. J Geriatr Psychiatry Neurol 1994;7:(Suppl1):S47–S53. [DOI] [PubMed] [Google Scholar]
  • 35. Agrosi M, Mischiatti S, Harrasser PC, Savio D. Oral bioavailability of active principles from herbal products in humans: a study of Hypericum perforatum extracts using the soft gelatin capsule technology. Phytomedicine 2000;7:455–462. [DOI] [PubMed] [Google Scholar]
  • 36. Vitiello B, Shader RI, Parker CB, et al. Hyperforin plasma level as marker of treatment of adherence in the National Institutes of Health hypericum depression trial. Clin Psychopharmacol 2005;25:243–249. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Laboratory Analysis are provided here courtesy of Wiley

RESOURCES